title: Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
abstract: OBJECTIVE
  The incidence of intraductal papillary mucinous neoplasm (IPMN) is rising and these neoplasms now represent up to 25% of resected pancreatic neoplasms. The optimal postoperative management of resected invasive IPMN is still debated in the absence of large prospective clinical trials and of validated prognostic factors in this setting. The objective of our study was to identify potential prognostic factors and to investigate the role of adjuvant therapies for patients radically resected for invasive IPMN.
  
  
  METHODS
  We retrospectively reviewed clinical and pathological data regarding a large series of patients with invasive IPMN who underwent surgical resection in the last six years at University Hospital of Pisa.
  
  
  RESULTS
  Sixty-four patients were considered for the analysis, thirty-three of whom received adjuvant chemotherapy with gemcitabine. In our series node involvement and high tumoral grade emerged as the major pathologic prognostic factors. Patients treated with adjuvant chemotherapy with gemcitabine experienced a longer disease-free survival than those who received surgery alone.
  
  
  CONCLUSIONS
  Gemcitabine-based chemotherapy seems beneficial as adjuvant treatment for patients with resected invasive IPMN.
authors.affiliation: Department of Oncology, Transplants, and New Technologies, U.O. Oncologia 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Polo Oncologico Area Vasta Nord-Ovest, Istituto Toscano Tumori, Via Roma 67, 56126 Pisa, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Caponi
authors.forename: E
authors.initials: E
authors.lastname: Vasile
authors.forename: N
authors.initials: N
authors.lastname: Funel
authors.forename: N
authors.initials: N
authors.lastname: De Lio
authors.forename: D
authors.initials: D
authors.lastname: Campani
authors.forename: L
authors.initials: L
authors.lastname: Ginocchi
authors.forename: M
authors.initials: M
authors.lastname: Lucchesi
authors.forename: C
authors.initials: C
authors.lastname: Caparello
authors.forename: M
authors.initials: M
authors.lastname: Lencioni
authors.forename: C
authors.initials: C
authors.lastname: Cappelli
authors.forename: F
authors.initials: F
authors.lastname: Costa
authors.forename: L
authors.initials: L
authors.lastname: Pollina
authors.forename: S
authors.initials: S
authors.lastname: Ricci
authors.forename: F
authors.initials: F
authors.lastname: Mosca
authors.forename: A
authors.initials: A
authors.lastname: Falcone
authors.forename: U
authors.initials: U
authors.lastname: Boggi
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine